In this candid conversation, Lou Basenese sits down with Gene Mack, CEO of Gain Therapeutics, to reveal how the company is leveraging AI to unlock billion-dollar opportunities in rare and neurodegenerative diseases. Mack highlights a striking disconnect: a $70 million company with a Phase 2 Parkinson’s drug that could be disease-modifying. He outlines Gain’s vast revenue potential and why future therapies will be measured against its first-in-class platform.